Benchmark raised the firm’s price target on Ligand (LGND) to $160 from $135 and keeps a Buy rating on the shares after the company reported better-than-expected Q2 results and raised FY25 guidance. For FY25, the firm is now forecasting that Ligand will grow revenue 29% year-over-year to $215M with adjusted EPS of $6.85, up from $5.72 last year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $185 from $155 at RBC Capital
- Ligand Pharmaceuticals Reports Strong Q2 2025 Results
- Positive Outlook on Ligand Pharma: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Ligand raises FY25 adjusted EPS view to $6.70-$7.00 from $6.00-$6.25
- Ligand reports Q2 adjusted EPS $1.60, consensus $1.42